Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
| trading_symbol | registrant_name | time | price | change | percentage_change | 
|---|---|---|---|---|---|
| CVM | CEL SCI CORP | 2025-10-30 18:44:08 | 6.62 | -0.02 | -0.3 | 
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVM | 0000725363 | CEL SCI CORP | US1508377066 | 549300FIWOFSETIVMI17 | 840916344 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 0930 | CO | 8229 BOONE BLVD . | VIENNA | VA | 22182 | UNITED STATES | US | 7035069460 | 8229 BOONE BLVD., VIENNA, VA, 22182 | 8229 BOONE BLVD ., VIENNA, VA, 22182 | — | — | 1983 | — | — | https://cel-sci.com/ | 100,002,189 | 5,321,341 | 6,882,156 | Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. | 2025-10-30 16:43:18 | 
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding | 
|---|---|---|---|---|---|---|
| 2024 | 100,002,189 | 2,362,894 | 2.42 | 74,107,041 | 24,126,237 | 48.271 | 
| 2023 | 97,639,295 | -65,929,498 | -40.3069 | 49,980,804 | 6,300,941 | 14.4253 | 
| 2022 | 163,568,793 | -431,969,114 | -72.5343 | 43,679,863 | 435,365 | 1.0068 | 
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation | 
|---|---|---|---|---|---|---|---|---|
| Eyal Talor | Chief Scientific Officer | 2024 | 349,612 | 0 | 9,600 | — | 6,031 | 613,023 | 
| John Cipriano | Senior Vice President | 2024 | 249,562 | 0 | 0 | — | 31 | 249,593 | 
| Geert R. Kersten | Chief Executive And Financial Officer, Treasurer | 2024 | 644,091 | 0 | 20,475 | — | 65,631 | 1,070,554 | 
| Patricia B. Prichep | Secretary, Senior Vice President | 2024 | 289,194 | 0 | 17,160 | — | 9,031 | 542,744 | 
| Daniel Zimmerman, Ph.D. | Senior Vice President | 2023 | 45,546 | 0 | 0 | — | 531 | 46,077 | 
| Fiscal Year | Employee Count | 
|---|---|
| 2011 | 44 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Revenue | — | — | — | 
| Cost Of Revenue | — | — | — | 
| Gross Profit | — | — | — | 
| Research And Development Expenses | 18,161,451 | 22,471,496 | 25,355,346 | 
| General And Administrative Expenses | 8,191,023 | 9,004,578 | 10,707,447 | 
| Operating Expenses | 26,352,474 | 31,476,074 | 36,062,793 | 
| Operating Income | -26,352,474 | -31,476,074 | -36,062,793 | 
| Net Income | -27,579,921 | -32,194,303 | -36,700,681 | 
| Earnings Per Share Basic | — | -0.73 | -0.87 | 
| Earnings Per Share Diluted | -0.51 | — | -0.87 | 
| Weighted Average Shares Outstanding Basic | — | 44,479,865 | 43,148,888 | 
| Weighted Average Shares Outstanding Diluted | 54,044,989 | — | 43,148,888 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Cash And Cash Equivalents | 4,738,173 | 4,145,735 | 22,672,138 | 
| Marketable Securities Current | — | — | 0 | 
| Accounts Receivable | — | — | 0 | 
| Inventories | 1,019,908 | 2,248,072 | 2,001,715 | 
| Non Trade Receivables | — | — | — | 
| Other Assets Current | 294,097 | 520,368 | 762,063 | 
| Total Assets Current | 6,055,678 | 6,918,420 | 25,435,916 | 
| Marketable Securities Non Current | — | — | — | 
| Property Plant And Equipment | 8,129,753 | 10,188,126 | 11,889,029 | 
| Other Assets Non Current | — | — | — | 
| Total Assets Non Current | 20,936,088 | 23,609,830 | 25,087,790 | 
| Total Assets | 26,991,766 | 30,528,250 | 50,523,706 | 
| Accounts Payable | 1,448,467 | 2,009,786 | 1,618,290 | 
| Deferred Revenue | — | — | — | 
| Short Term Debt | — | — | — | 
| Other Liabilities Current | 566,042 | 1,049,581 | 842,492 | 
| Total Liabilities Current | 4,615,779 | 5,585,846 | 4,663,751 | 
| Long Term Debt | — | 9,949,000 | — | 
| Other Liabilities Non Current | 125,000 | 125,000 | 125,000 | 
| Total Liabilities Non Current | 9,508,904 | 11,727,514 | 13,696,748 | 
| Total Liabilities | 14,124,683 | 17,313,360 | 18,360,499 | 
| Common Stock | 637,870 | 474,223 | 434,484 | 
| Retained Earnings | -514,011,861 | -487,091,396 | -454,897,093 | 
| Accumulated Other Comprehensive Income | — | — | — | 
| Total Shareholders Equity | 12,867,083 | 13,214,890 | 32,163,207 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Depreciation And Amortization | 3,969,183 | 3,958,334 | 3,828,917 | 
| Share Based Compensation Expense | 4,270,180 | 6,286,231 | 11,389,932 | 
| Other Non Cash Income Expense | — | — | 0 | 
| Change In Accounts Receivable | — | — | -54,922 | 
| Change In Inventories | 172,608 | -156,727 | 159,430 | 
| Change In Non Trade Receivables | — | — | — | 
| Change In Other Assets | — | — | — | 
| Change In Accounts Payable | -460,576 | 257,845 | 374,890 | 
| Change In Other Liabilities | -458,489 | 207,089 | -16,724 | 
| Cash From Operating Activities | -18,811,206 | -22,848,561 | -18,240,951 | 
| Purchases Of Marketable Securities | — | — | — | 
| Sales Of Marketable Securities | — | — | — | 
| Acquisition Of Property Plant And Equipment | 94,875 | 361,892 | 637,892 | 
| Acquisition Of Business | — | — | — | 
| Other Investing Activities | — | — | — | 
| Cash From Investing Activities | -108,086 | -372,262 | 5,491,367 | 
| Tax Withholding For Share Based Compensation | — | — | — | 
| Payments Of Dividends | — | — | — | 
| Issuance Of Common Stock | 23,575,000 | — | — | 
| Repurchase Of Common Stock | — | — | — | 
| Issuance Of Long Term Debt | — | — | — | 
| Repayment Of Long Term Debt | — | — | — | 
| Other Financing Activities | 80,620 | — | — | 
| Cash From Financing Activities | 19,511,730 | 4,694,420 | -638,426 | 
| Change In Cash | 592,438 | -18,526,403 | -13,388,010 | 
| Cash At End Of Period | 4,738,173 | 4,145,735 | 22,672,138 | 
| Income Taxes Paid | — | — | — | 
| Interest Paid | 923,807 | 1,062,564 | 1,157,069 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Earnings Per Share | — | -0.73 | -0.87 | 
| Price To Earnings Ratio | — | -51.3751 | -106.5624 | 
| Earnings Growth Rate | — | -16.092 | -3.3333 | 
| Price Earnings To Growth Ratio | — | 3.1926 | 31.9687 | 
| Book Value Per Share | — | 0.2971 | 0.7454 | 
| Price To Book Ratio | — | 126.2337 | 124.3751 | 
| Ebitda | -22,865,065 | -27,560,553 | -33,952,798 | 
| Enterprise Value | — | 1,673,967,225.987 | — | 
| Dividend Yield | — | — | — | 
| Dividend Payout Ratio | — | — | — | 
| Debt To Equity Ratio | — | 0.7529 | — | 
| Capital Expenditures | 1,910,810 | 2,257,431 | 2,054,384 | 
| Free Cash Flow | -20,722,016 | -25,105,992 | -20,295,335 | 
| Return On Equity | -2.1434 | -2.4362 | -1.1411 | 
| One Year Beta | 1.574 | 1.0871 | 1.5539 | 
| Three Year Beta | 1.4194 | 1.0251 | 0.7803 | 
| Five Year Beta | 0.8814 | 0.9357 | 0.9467 | 
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction | 
|---|---|---|---|---|---|
| KERSTEN GEERT R | Director, Chief Executive Officer | 2025-09-30 | 570 | A | 73,405 | 
| PRICHEP PATRICIA B | Chief Financial Officer | 2025-09-30 | 466 | A | 11,213 | 
| TALOR EYAL | Chief Scientific Officer | 2025-09-30 | 260 | A | 5,808 | 
| KERSTEN GEERT R | Director, Chief Executive Officer | 2025-07-28 | 25,000 | A | 175,157 | 
| PRICHEP PATRICIA B | Chief Financial Officer | 2025-07-28 | 12,000 | A | 75,127 | 
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security | 
|---|---|---|---|---|
| Darwin Wealth Management, LLC | 2025-09-30 | 9 | 1 | 9 | 
| City State Bank | 2025-09-30 | 616 | 67 | 9.194 | 
| AdvisorNet Financial, Inc | 2025-09-30 | 892 | 97 | 9.1959 | 
| OSAIC HOLDINGS, INC. | 2025-06-30 | 35,552 | 15,530 | 2.2892 | 
| MORGAN STANLEY | 2025-06-30 | 1,115 | 487 | 2.2895 | 
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets | 
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 3,455 | 36,035.65 | 0.0 | 
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 3,848 | 40,134.64 | 0.0 | 
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 13,731 | 143,214.33 | 0.0003 | 
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 29,909 | 68,491.61 | 0.0001 | 
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 29,909 | 68,491.61 | 0.0001 |